Literature DB >> 28289790

[New therapy approaches for Parkinson's disease].

K Brockmann1, D Berg2,3.   

Abstract

Over the last years major advances have been made in the identification of specific pathways underlying the pathophysiology of subgroups of patients with Parkinson' disease. These pathways include mitochondrial and lysosomal dysfunction as well as inflammatory patterns and represent the basis for new causative and disease-modifying treatment strategies, possibly not only for the respective subgroups of patients but hopefully also for the majority of patients with idiopathic Parkinson's disease. This article highlights the main treatment strategies focusing on causative and disease course-modifying strategies as well as quality of life.

Entities:  

Keywords:  Antibodies; Genetics; Inflammation; Iron; Quality of life

Mesh:

Year:  2017        PMID: 28289790     DOI: 10.1007/s00115-017-0299-x

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  37 in total

1.  Association between high-sensitivity C-reactive protein and risk of early idiopathic Parkinson's disease.

Authors:  In-Uk Song; Sung-Woo Chung; Joong-Seok Kim; Kwang-Soo Lee
Journal:  Neurol Sci       Date:  2010-06-08       Impact factor: 3.307

2.  Effect of endogenous mutant and wild-type PINK1 on Parkin in fibroblasts from Parkinson disease patients.

Authors:  Aleksandar Rakovic; Anne Grünewald; Philip Seibler; Alfredo Ramirez; Norman Kock; Slobodanka Orolicki; Katja Lohmann; Christine Klein
Journal:  Hum Mol Genet       Date:  2010-05-27       Impact factor: 6.150

3.  Targeting chelatable iron as a therapeutic modality in Parkinson's disease.

Authors:  David Devos; Caroline Moreau; Jean Christophe Devedjian; Jérome Kluza; Maud Petrault; Charlotte Laloux; Aurélie Jonneaux; Gilles Ryckewaert; Guillaume Garçon; Nathalie Rouaix; Alain Duhamel; Patrice Jissendi; Kathy Dujardin; Florent Auger; Laura Ravasi; Lucie Hopes; Guillaume Grolez; Wance Firdaus; Bernard Sablonnière; Isabelle Strubi-Vuillaume; Noel Zahr; Alain Destée; Jean-Christophe Corvol; Dominik Pöltl; Marcel Leist; Christian Rose; Luc Defebvre; Philippe Marchetti; Z Ioav Cabantchik; Régis Bordet
Journal:  Antioxid Redox Signal       Date:  2014-02-06       Impact factor: 8.401

4.  Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair.

Authors:  Oliver Rothfuss; Heike Fischer; Takafumi Hasegawa; Martina Maisel; Petra Leitner; Franziska Miesel; Manu Sharma; Antje Bornemann; Daniela Berg; Thomas Gasser; Nadja Patenge
Journal:  Hum Mol Genet       Date:  2009-07-19       Impact factor: 6.150

5.  Risk factors and prodromal markers and the development of Parkinson's disease.

Authors:  Stefanie Lerche; Klaus Seppi; Stefanie Behnke; Inga Liepelt-Scarfone; Jana Godau; Philipp Mahlknecht; Alexandra Gaenslen; Kathrin Brockmann; Karin Srulijes; Heiko Huber; Isabel Wurster; Heike Stockner; Stefan Kiechl; Johann Willeit; Arno Gasperi; Klaus Fassbender; Werner Poewe; Daniela Berg
Journal:  J Neurol       Date:  2013-11-05       Impact factor: 4.849

6.  Neurostimulation for Parkinson's disease with early motor complications.

Authors:  W M M Schuepbach; J Rau; K Knudsen; J Volkmann; P Krack; L Timmermann; T D Hälbig; H Hesekamp; S M Navarro; N Meier; D Falk; M Mehdorn; S Paschen; M Maarouf; M T Barbe; G R Fink; A Kupsch; D Gruber; G-H Schneider; E Seigneuret; A Kistner; P Chaynes; F Ory-Magne; C Brefel Courbon; J Vesper; A Schnitzler; L Wojtecki; J-L Houeto; B Bataille; D Maltête; P Damier; S Raoul; F Sixel-Doering; D Hellwig; A Gharabaghi; R Krüger; M O Pinsker; F Amtage; J-M Régis; T Witjas; S Thobois; P Mertens; M Kloss; A Hartmann; W H Oertel; B Post; H Speelman; Y Agid; C Schade-Brittinger; G Deuschl
Journal:  N Engl J Med       Date:  2013-02-14       Impact factor: 91.245

Review 7.  Peripheral chemo-cytokine profiles in Alzheimer's and Parkinson's diseases.

Authors:  M Reale; N H Greig; M A Kamal
Journal:  Mini Rev Med Chem       Date:  2009-09       Impact factor: 3.862

Review 8.  Neuropathological basis of nonmotor manifestations of Parkinson's disease.

Authors:  Charles H Adler; Thomas G Beach
Journal:  Mov Disord       Date:  2016-03-31       Impact factor: 10.338

9.  Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.

Authors:  Ju-Hee Kang; David J Irwin; Alice S Chen-Plotkin; Andrew Siderowf; Chelsea Caspell; Christopher S Coffey; Teresa Waligórska; Peggy Taylor; Sarah Pan; Mark Frasier; Kenneth Marek; Karl Kieburtz; Danna Jennings; Tanya Simuni; Caroline M Tanner; Andrew Singleton; Arthur W Toga; Sohini Chowdhury; Brit Mollenhauer; John Q Trojanowski; Leslie M Shaw
Journal:  JAMA Neurol       Date:  2013-10       Impact factor: 18.302

10.  Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models.

Authors:  Alvaro Sanchez-Martinez; Michelle Beavan; Matthew E Gegg; Kai-Yin Chau; Alexander J Whitworth; Anthony H V Schapira
Journal:  Sci Rep       Date:  2016-08-19       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.